Gabapentin
Discover related
5 sources
🧬 Receptor activity
| Target | Action | Affinity | Source | |
|---|---|---|---|---|
| Potassium voltage-gated channel subfamily KQT member 3 (KCNQ3) | Activator | 8.28 EC50 | DRUGCENTRAL | TargetPotassium voltage-gated channel subfamily KQT member 3 (KCNQ3) ActionActivator Affinity8.28 EC50 SourceDRUGCENTRAL |
| Potassium voltage-gated channel subfamily KQT member 5 (KCNQ5) | Activator | 8.72 EC50 | DRUGCENTRAL | TargetPotassium voltage-gated channel subfamily KQT member 5 (KCNQ5) ActionActivator Affinity8.72 EC50 SourceDRUGCENTRAL |
| Voltage-dependent calcium channel subunit alpha-2/delta-1 (CACNA2D1) | Modulator | 7.26 IC50 | DRUGCENTRAL | TargetVoltage-dependent calcium channel subunit alpha-2/delta-1 (CACNA2D1) ActionModulator Affinity7.26 IC50 SourceDRUGCENTRAL |
| Voltage-dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2) | Modulator | 6.928 IC50 | DRUGCENTRAL | TargetVoltage-dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2) ActionModulator Affinity6.928 IC50 SourceDRUGCENTRAL |
| Adenosine receptor A1 (ADORA1) | — | — | DRUGCENTRAL | TargetAdenosine receptor A1 (ADORA1) Action— Affinity— SourceDRUGCENTRAL |
| Alpha-2A adrenergic receptor (ADRA2A) | — | — | DRUGCENTRAL | TargetAlpha-2A adrenergic receptor (ADRA2A) Action— Affinity— SourceDRUGCENTRAL |
| Gamma-aminobutyric acid type B receptor subunit 2 (GABBR2) | — | — | DRUGCENTRAL | TargetGamma-aminobutyric acid type B receptor subunit 2 (GABBR2) Action— Affinity— SourceDRUGCENTRAL |
| Glutamate receptor ionotropic, NMDA 3A (GRIN3A) | — | — | DRUGCENTRAL | TargetGlutamate receptor ionotropic, NMDA 3A (GRIN3A) Action— Affinity— SourceDRUGCENTRAL |
| Large neutral amino acids transporter small subunit 1 (SLC7A5) | — | 4.523 IC50 | DRUGCENTRAL | TargetLarge neutral amino acids transporter small subunit 1 (SLC7A5) Action— Affinity4.523 IC50 SourceDRUGCENTRAL |
| Sodium channel protein type 5 subunit alpha (SCN5A) | — | — | DRUGCENTRAL | TargetSodium channel protein type 5 subunit alpha (SCN5A) Action— Affinity— SourceDRUGCENTRAL |
| Uncharacterized protein; Voltage-dependent calcium channel alpha-2 delta subunit (CACNA2D1) | — | 7.15 IC50 | DRUGCENTRAL | TargetUncharacterized protein; Voltage-dependent calcium channel alpha-2 delta subunit (CACNA2D1) Action— Affinity7.15 IC50 SourceDRUGCENTRAL |
| Voltage-dependent calcium channel subunit alpha-2/delta-1 (Cacna2d1) | — | 6.92 Ki | DRUGCENTRAL | TargetVoltage-dependent calcium channel subunit alpha-2/delta-1 (Cacna2d1) Action— Affinity6.92 Ki SourceDRUGCENTRAL |
External links
PubChem 3446 ↗CAS 1126623-20-8 ↗CAS 60142-96-3 ↗KEGG C07018 ↗ChEBI CHEBI:42797 ↗ChEMBL CHEMBL940 ↗KEGG D00332 ↗DrugBank DB00996 ↗NIH ↗NIH ↗ChemSpider ↗ChEBI/ChEMBL ↗ChEBI/ChEMBL ↗Guide to Pharmacology ↗NIH ↗NIH ↗NIH ↗NIH ↗NIH ↗DrugBank ↗ChEBI/ChEMBL ↗NIH ↗NIH ↗NIH ↗NIH ↗NIH ↗CAS 1185039-20-6 ↗CAS 360-70-3 ↗PsychonautWiki ↗Erowid ↗Experience reports (PiHKAL) ↗Experience reports (TiHKAL) ↗
Source: DrugCentral — Gabapentin ↗
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.